| 29.31 -0.95 (-3.14%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 38.35 | 1-year : | 41.39 |
| Resists | First : | 32.83 | Second : | 35.43 |
| Pivot price | 30.44 |
|||
| Supports | First : | 28.62 | Second : | 23.82 |
| MAs | MA(5) : | 29.72  |
MA(20) : | 31.22 |
| MA(100) : | 29.64 |
MA(250) : | 30 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 21.3 |
D(3) : | 20.7 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 38.09 | Low : | 21.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SUPN ] has closed above bottom band by 28.3%. Bollinger Bands are 47.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 30.24 - 30.4 | 30.4 - 30.5 |
| Low: | 28.81 - 29.01 | 29.01 - 29.14 |
| Close: | 29.02 - 29.32 | 29.32 - 29.52 |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Wed, 24 Apr 2024
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 - Yahoo Finance
Wed, 24 Apr 2024
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price - Simply Wall St
Sat, 20 Apr 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals ... - PR Newswire
Wed, 17 Apr 2024
Notable Two Hundred Day Moving Average Cross - SUPN - Nasdaq
Mon, 08 Apr 2024
Supernus stock slides as FDA rejects Parkinson's disease infusion device (NASDAQ:SUPN) - Seeking Alpha
Mon, 08 Apr 2024
Supernus Provides Regulatory Update for SPN-830 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 55 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 108.1 (%) |
| Shares Short | 4,820 (K) |
| Shares Short P.Month | 4,410 (K) |
| EPS | 0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.84 |
| Profit Margin | 0.2 % |
| Operating Margin | 11.5 % |
| Return on Assets (ttm) | 0.5 % |
| Return on Equity (ttm) | 0.1 % |
| Qtrly Rev. Growth | -1.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 11.1 |
| EBITDA (p.s.) | 1.79 |
| Qtrly Earnings Growth | -96 % |
| Operating Cash Flow | 111 (M) |
| Levered Free Cash Flow | 162 (M) |
| PE Ratio | 1465.5 |
| PEG Ratio | 10.4 |
| Price to Book value | 1.74 |
| Price to Sales | 2.64 |
| Price to Cash Flow | 14.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|